AI Article Synopsis

  • Human hepatocyte growth factor (hHGF) was purified from the plasma of patients with severe liver failure due to hepatitis B and non-A, non-B hepatitis, revealing two major protein bands with weights of 79,000 and 86,000.
  • After undergoing reduction, the hHGF displayed three major protein bands at different molecular weights, and its activity was lost upon this reduction.
  • The purified hHGF showed a measurable effect on DNA synthesis in cultured liver cells, and its concentration in patients with severe hepatic coma was found to be between 1.8-3.0 nM, with no evidence that it is related to human albumin.

Article Abstract

Human hepatocyte growth factor (hHGF) was purified from the plasma of six patients with fulminant hepatic failure due to hepatitis B in two and non-A, non-B hepatitis in four. The purified hHGF from each patient contained two major protein bands having molecular weights of 79,000 and 86,000 and several minor bands having molecular weights between 76,000 and 92,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis performed under nonreduced conditions. After reduction with 2-mercaptoethanol, three major bands having molecular weights of 58,000, 34,500, and 31,500 were evident. In addition, a band having a molecular weight of 21,000 was detected. hHGF activity was destroyed by its reduction. The hHGF purified from patients demonstrated a dose response in terms of an increase in DNA synthesis using cultured hepatocytes. The hHGF concentration in the plasma of the patients with grade III-IV hepatic coma was calculated to be in the range of 1.8-3.0 nM. Finally the heavy chain of hHGF was not recognized by an anti-human albumin antibody, indicating that hHGF is not biliprotein, an albumin-bilirubin complex, that has been reported to be a putative liver growth factor.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF01311238DOI Listing

Publication Analysis

Top Keywords

growth factor
12
bands molecular
12
molecular weights
12
human hepatocyte
8
hepatocyte growth
8
patients fulminant
8
fulminant hepatic
8
hepatic failure
8
hhgf purified
8
plasma patients
8

Similar Publications

Objectives: To determine the top 100 cited authors and the top 20 articles in the Journal of Orthopaedic Trauma (JOT) and compare its impact factor to orthopaedic and non-orthopaedic surgery literature.

Design: Review.

Methods: The Web of Science database was used to determine the top 100 cited authors and top 20 cited articles that originated in JOT from 1995 to the present.

View Article and Find Full Text PDF

Background: Glioblastoma is an aggressive brain cancer with a 5-year survival rate of 5-10%. Current therapeutic options are limited, due in part to drug exclusion by the blood-brain barrier, restricting access of targeted drugs to the tumor. The receptor for the type 1 insulin-like growth factor (IGF-1R) was identified as a therapeutic target in glioblastoma.

View Article and Find Full Text PDF

Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC.

View Article and Find Full Text PDF

Specific immunohistochemical expression of Mmp-26 in prostatic adenocarcinoma.

An Acad Bras Cienc

January 2025

Universidade Federal de Pernambuco, Departamento de Histologia e Embriologia, Av. Prof. Moraes Rego, 1235, Cidade Universitária, 50760-420 Recife, PE, Brazil.

Matrix metalloproteinases (MMP) have been identified as biomarkers for several diseases, including cancer. The increase in the expression of these enzymes has been related to greater tumor aggressiveness. MMP-26 is expressed constitutively in the endometrium and some cancer cells of epithelial origin.

View Article and Find Full Text PDF

Background: Insulin resistance often occurs in patients with chronic kidney disease (CKD) owing to mineral and bone metabolism disorders. Fibroblast growth factor (FGF)-23 and soluble klotho (s-KL) play crucial roles in linking CKD with mineral and bone metabolism.

Objective: This study aimed to examine the relationship between insulin resistance and FGF-23 and s-KL in patients with non-diabetic pre-dialysis patients with CKD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!